Cécile Alanio

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Vaccine-induced ICOS<sup>+</sup>CD38<sup>+</sup> circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathway
  2021 L1 88/100

1 assessed by us (1 reproduced) · 144 not yet assessed — every PubMed paper on record, linked below.

• The dynamic myeloid-enriched microenvironment of glioblastoma: a major challenge to immunotherapy efficacy ↗

  Frontiers in Immunology · 2026 · PMID 41743721
  not yet assessed
• CMV seropositivity associates with poor clinical outcome in triple negative breast cancer ↗

  iScience · 2026 · PMID 41852722
  not yet assessed
• The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM ↗

  Cell · 2026 · PMID 42296961
  not yet assessed
• Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial ↗

  Nature Medicine · 2025 · PMID 40451950
  not yet assessed
• Structural basis for hepatitis E virus neutralization by potent human antibodies ↗

  Science Advances · 2025 · PMID 40333967
  not yet assessed
• Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade ↗

  Cancer Cell · 2025 · PMID 41478278
  not yet assessed
• Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial ↗

  Nature Medicine · 2025 · PMID 40500416
  not yet assessed
• Antigen-Specific Profiling Identifies T-bet-Expressing Melanoma-Specific CD8 T Cells Associated with Pathologic Response to Neoadjuvant Anti-PD-1 ↗

  SSRN Electronic Journal · 2025
  not yet assessed
• Longitudinal evolution of tumor and immune system after intracranial CAR T cell therapy in recurrent GBM ↗

  Cytotherapy · 2025
  not yet assessed
• P02.09.B SURGICAL RESECTION OF GLIOBLASTOMA INDUCES IMMUNOSUPPRESSION ↗

  Neuro-Oncology · 2025
  not yet assessed
• OS05.7.A NEUROSURGERY IN GLIOBLASTOMA INDUCES CELL PLASTICITY, THERAPY RESISTANCE AND IMMUNOSUPPRESSION BY ISCHEMIC HYPOXIA ↗

  Neuro-Oncology · 2025
  not yet assessed
• DDDR-63. Immune remodeling in CSF and tumor predicts response to CAR T therapy in glioblastoma ↗

  Neuro-Oncology · 2025
  not yet assessed
• Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial ↗

  Nature Cancer · 2024 · PMID 38216766
  not yet assessed
• Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells ↗

  Cancer Cell · 2024 · PMID 39214097
  not yet assessed
• Optimisation de l’efficacité et de la sécurité d’utilisation des lymphocytes CAR-T ↗

  médecine/sciences · 2024 · PMID 38819280
  not yet assessed
• Supplementary Table 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Data from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Data from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Data from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 2 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 3 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Supplementary Table 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  2024
  not yet assessed
• Selective control of transposable element expression during T cell exhaustion and anti–PD-1 treatment ↗

  Science Immunology · 2023 · PMID 37889984
  not yet assessed
• CTIM-24. REPEATED PERIPHERAL INFUSIONS OF ANTI-EGFRVIII CAR T CELLS IN COMBINATION WITH PEMBROLIZUMAB REMODELS THE TUMOR MICROENVIRONMENT IN DE NOVO GLIOBLASTOMA ↗

  Neuro-Oncology · 2023
  not yet assessed
• Phase I study of repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab in patients with newly diagnosed, MGMT-unmethylated glioblastoma ↗

  Research Square · 2023
  not yet assessed
• Reinvigoration of Progenitor-Exhausted CD8 T Cells by anti-CTLA-4 Contributes to the Sustained Activity of Combination Checkpoint Blockade ↗

  SSRN Electronic Journal · 2023
  not yet assessed
• Supplementary Figure 6 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Table 2 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 2 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 5 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Table 1 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 4 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 3 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 1 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Methods and Materials from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Table 1 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 6 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 3 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 5 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 1 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 2 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Methods and Materials from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Figure 4 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Supplementary Table 2 from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Data from Immunologic Features in <i>De Novo</i> and Recurrent Glioblastoma Are Associated with Survival Outcomes ↗

  2023
  not yet assessed
• Data from Immunologic Features in <i>De Novo</i> and Recurrent Glioblastoma Are Associated with Survival Outcomes ↗

  2023
  not yet assessed
• Supplementary Figure from Immunologic Features in <i>De Novo</i> and Recurrent Glioblastoma Are Associated with Survival Outcomes ↗

  2023
  not yet assessed
• Supplementary Figure from Immunologic Features in <i>De Novo</i> and Recurrent Glioblastoma Are Associated with Survival Outcomes ↗

  2023
  not yet assessed
• 579-C Reinvigoration of progenitor-exhausted CD8 T cells by anti-CTLA-4 contributes to the sustained activity of combination checkpoint blockade ↗

  2023
  not yet assessed
• 5 Severely immunodeficient NOG-EXL mice allow for humanization and development of a human glioblastoma-derived tumor microenvironment ↗

  Regular and Young Investigator Award Abstracts · 2023
  not yet assessed
• MODL-10. SEVERELY IMMUNODEFICIENT NOG-EXL MICE ALLOW FOR HUMANIZATION AND DEVELOPMENT OF A HUMAN GLIOBLASTOMA-DERIVED TUMOR MICROENVIRONMENT ↗

  Neuro-Oncology · 2023
  not yet assessed
• Data from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Data from PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  2023
  not yet assessed
• Decade-long leukaemia remissions with persistence of CD4+ CAR T cells ↗

  Nature · 2022 · PMID 35110735
  not yet assessed
• Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial ↗

  Nature Medicine · 2022 · PMID 35662283
  not yet assessed
• Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides ↗

  Cell Reports · 2022 · PMID 35675780
  not yet assessed
• Cytomegalovirus Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization ↗

  The Journal of Infectious Diseases · 2022 · PMID 35134186
  not yet assessed
• Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19 ↗

  Frontiers in Immunology · 2022 · PMID 35309299
  not yet assessed
• Primary immune responses are negatively impacted by persistent herpesvirus infections in older people: results from an observational study on healthy subjects and a vaccination trial on subjects aged more than 70 years old ↗

  EBioMedicine · 2022 · PMID 35114631
  not yet assessed
• Immunologic Features in <i>De Novo</i> and Recurrent Glioblastoma Are Associated with Survival Outcomes ↗

  Cancer Immunology Research · 2022 · PMID 35507919
  not yet assessed
• Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells ↗

  Nature · 2022 · PMID 36477542
  not yet assessed
• CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer ↗

  Nature Medicine · 2021 · PMID 34017137
  not yet assessed
• Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection ↗

  Cell · 2021 · PMID 33631096
  not yet assessed
• Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19 ↗

  Science Immunology · 2021 · PMID 33653907
  not yet assessed
• Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy ↗

  Blood · 2021 · PMID 34496014
  not yet assessed
• Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer ↗

  Clinical Cancer Research · 2021 · PMID 34112709
  not yet assessed
• Vaccine-induced ICOS+CD38+ circulating Tfh are sensitive biosensors of age-related changes in inflammatory pathways

  Cell Reports Medicine · 2021 · PMID 34095875
  L1 88/100
• Subsetting the subsets: Heterogeneity and developmental relationships of T cells in human tumors ↗

  Science Immunology · 2021 · PMID 34301801
  not yet assessed
• IMMU-38. DEEP IMMUNOPROFILING OF HUMAN GLIOBLASTOMA (GBM) REVEALS DIFFERENCES IN THE TUMOR IMMUNE CELL INFILTRATE IN PATIENTS WITH HIGH VS. LOW PLASMA CELL-FREE DNA (CFDNA) ↗

  Neuro-Oncology · 2021
  not yet assessed
• CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer ↗

  Research Square · 2021 · PMID 33564756
  not yet assessed
• Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19 ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2021 · PMID 33972943
  not yet assessed
• Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells ↗

  Blood · 2021
  not yet assessed
• Decade-long remissions of leukemia sustained by the persistence of activated CD4 ⁺ CAR T-cells ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2021
  not yet assessed
• Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells ↗

  Research Square · 2021
  not yet assessed
• Immunological features of de novo and recurrent glioblastoma associate with survival in glioblastoma ↗

  Cytotherapy · 2021
  not yet assessed
• Abstract CT005: T cell inflammation in the tumor microenvironment after agonist CD40 antibody: Clinical and translational results of a neoadjuvant clinical trial ↗

  Cancer Research · 2021
  not yet assessed
• Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications ↗

  Science · 2020 · PMID 32669297
  not yet assessed
• CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study ↗

  The Lancet Oncology · 2020 · PMID 33387490
  not yet assessed
• Exploration of T-Cell Diversity Using Mass Cytometry ↗

  Methods in molecular biology · 2020 · PMID 31933194
  not yet assessed
• Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2020 · PMID 32511371
  not yet assessed
• Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection ↗

  medRxiv · 2020 · PMID 33200143
  not yet assessed
• Deep Immune Profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19 ↗

  medRxiv · 2020 · PMID 32995826
  not yet assessed
• Abstract LB-356: Deep immune profiling of de novo and recurrent glioblastoma ↗

  Cancer Research · 2020
  not yet assessed
• A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals ↗

  Microbiome · 2019 · PMID 31519223
  not yet assessed
• A Comprehensive Assessment of Demographic, Environmental and Host Genetic Associations with Gut Microbiome Diversity in Healthy Individuals ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2019
  not yet assessed
• Vaccine-induced ICOS+CD38+ cTfh are sensitive biosensors of age-related changes in inflammatory pathways ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2019
  not yet assessed
• Abstract A123: Skewed CD4 and CD8 T-cell differentiation in pancreatic cancer patients ↗

  Cancer Immunology Research · 2019
  not yet assessed
• A Comprehensive Assessment of Demographic, Environmental and Host Genetic Associations with Gut Microbiome Diversity in Healthy Individuals (GWAS) ↗

  Zenodo (CERN European Organization for Nuclear Research) · 2019
  not yet assessed
• A Comprehensive Assessment of Demographic, Environmental and Host Genetic Associations with Gut Microbiome Diversity in Healthy Individuals (Metadata) ↗

  Figshare · 2019
  not yet assessed
• A Comprehensive Assessment of Demographic, Environmental and Host Genetic Associations with Gut Microbiome Diversity in Healthy Individuals (GWAS) ↗

  Zenodo (CERN European Organization for Nuclear Research) · 2019
  not yet assessed
• A Comprehensive Assessment of Demographic, Environmental and Host Genetic Associations with Gut Microbiome Diversity in Healthy Individuals (16S rRNA gene sequencing data) ↗

  Zenodo (CERN European Organization for Nuclear Research) · 2019
  not yet assessed
• A Comprehensive Assessment of Demographic, Environmental and Host Genetic Associations with Gut Microbiome Diversity in Healthy Individuals (Metadata) ↗

  Zenodo (CERN European Organization for Nuclear Research) · 2019
  not yet assessed
• A Comprehensive Assessment of Demographic, Environmental and Host Genetic Associations with Gut Microbiome Diversity in Healthy Individuals (16S rRNA gene sequencing data) ↗

  Figshare · 2019
  not yet assessed
• Additional File 2: ↗

  Figshare · 2019
  not yet assessed
• Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors ↗

  Nature Immunology · 2018 · PMID 29476184
  not yet assessed
• Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines ↗

  Genome Medicine · 2018 · PMID 30053915
  not yet assessed
• Human thymopoiesis is influenced by a common genetic variant within the <i>TCRA-TCRD</i> locus ↗

  Science Translational Medicine · 2018 · PMID 30185651
  not yet assessed
• Publisher Correction: Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors ↗

  Nature Immunology · 2018 · PMID 29725081
  not yet assessed
• Genetic factors and age are the strongest predictors of humoral immune responses to common pathogens and vaccines ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2018
  not yet assessed
• Human Genetic Variants And Age Are The Strongest Predictors Of Humoral Immune Responses To Common Pathogens And Vaccines ↗

  Zenodo (CERN European Organization for Nuclear Research) · 2018
  not yet assessed
• Human Genetic Variants And Age Are The Strongest Predictors Of Humoral Immune Responses To Common Pathogens And Vaccines ↗

  Zenodo (CERN European Organization for Nuclear Research) · 2018
  not yet assessed
• Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder ↗

  Journal of Hepatology · 2017 · PMID 28860025
  not yet assessed
• CXCR3/CXCL10 Axis Shapes Tissue Distribution of Memory Phenotype CD8+ T Cells in Nonimmunized Mice ↗

  The Journal of Immunology · 2017 · PMID 29187588
  not yet assessed
• Régression d’une lymphoprolifération CD30+ après traitement antiviral pour une hépatite E chronique ↗

  Annales de Dermatologie et de Vénéréologie · 2017
  not yet assessed
• Running title: Enumeration of antigen-specific naive CD8 T cells

  2016
  not yet assessed
• Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection ↗

  Blood · 2016
  not yet assessed
• The Milieu Intérieur study — An integrative approach for study of human immunological variance ↗

  Clinical Immunology · 2015 · PMID 25562703
  not yet assessed
• Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients ↗

  eLife · 2015 · PMID 26568315
  not yet assessed
• Author response: Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients ↗

  2015
  not yet assessed
• Baseline sensitivity of T cells to alpha‐<scp>IFN</scp> correlates with sustained virological response to <scp>IFN</scp>‐based triple therapy in <scp>HCV</scp> infection ↗

  Journal of Viral Hepatitis · 2014 · PMID 25382001
  not yet assessed
• PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer ↗

  Cancer Research · 2012 · PMID 23135914
  not yet assessed
• Tracking Antigen-Specific CD8+ T Cells Using MHC Class I Multimers ↗

  Methods in molecular biology · 2012 · PMID 23329496
  not yet assessed
• Enumeration of human antigen–specific naive CD8+ T cells reveals conserved precursor frequencies ↗

  Blood · 2010 · PMID 20200354
  not yet assessed
• A018 Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice ↗

  Archives of cardiovascular diseases · 2009
  not yet assessed
• Modulation of Macrophage Activation State Protects Tissue from Necrosis during Critical Limb Ischemia in Thrombospondin-1-Deficient Mice ↗

  PLoS ONE · 2008 · PMID 19079608
  not yet assessed
• Association between myeloid malignancies and acquired deficit in protein 4.1R: A retrospective analysis of six patients ↗

  American Journal of Hematology · 2007 · PMID 17994571
  not yet assessed
• À propos d’un profil électrophorétique atypique ↗

  Hématologie · 2006
  not yet assessed